Skip to main content

RT @hausmannMD: Anifrolumab, a type I IFN receptor antagonist, was effective in patients with SLE to increase BICLA response versus placebo…

Social Author Name
Jonathan Hausmann MD
Tweet Content
Anifrolumab, a type I IFN receptor antagonist, was effective in patients with SLE to increase BICLA response versus placebo. Results of the TULIP-2 trial. #ACR19 @RheumNow
Show on Archive Page
On
Display in Search Results
On
×